Kura Oncology (KURA)
13.25
+0.10 (0.76%)
Upcoming Events
Latest Headlines
Form 4 Kura Oncology, Inc. For: Aug 21 Filed by: Powl Brian T.
August 24, 2026 5:30 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Aug 24 Filed by: WILSON TROY EDWARD
August 24, 2026 5:30 PM - SEC Filing
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results
August 24, 2026 4:13 AM - StreetInsider
Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.
August 21, 2026 4:41 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Aug 19 Filed by: Bair Teresa Brophy
August 21, 2026 4:31 PM - SEC Filing
Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy
August 19, 2026 4:24 PM - SEC Filing
Form 4 Kura Oncology, Inc. For: Aug 17 Filed by: WILSON TROY EDWARD
August 17, 2026 4:45 PM - SEC Filing
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: MONTANOVA CAPITAL, LLC
August 14, 2026 4:32 PM - SEC Filing
Form 10-Q Kura Oncology, Inc. For: Jun 30
August 12, 2026 4:16 PM - SEC Filing
Form 8-K Kura Oncology, Inc. For: Aug 12
August 12, 2026 4:10 PM - SEC Filing
Kura Oncology (KURA) Tops Q2 EPS by 11c, Beats on Revenue
August 12, 2026 4:05 PM - StreetInsider
Kura Oncology Reports Second Quarter 2026 Financial Results
August 12, 2026 4:02 PM - Globe NewsWire
Kura Oncology publishes ziftomenib preclinical data in Blood journal
August 10, 2026 8:36 AM - StreetInsider
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
August 10, 2026 8:32 AM - Globe NewsWire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026 7:30 AM - Globe NewsWire
Kura Oncology to Report Second Quarter Financial Results
August 5, 2026 7:30 AM - Globe NewsWire
Form 8-K Kura Oncology, Inc. For: Jul 24
July 29, 2026 5:07 PM - SEC Filing
Kura Oncology reports Phase 1a data on darlifarnib combo in RCC
July 27, 2026 6:32 AM - StreetInsider
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
July 27, 2026 6:32 AM - Globe NewsWire
Leerink Assumes Kura Oncology (KURA) at Outperform
July 21, 2026 4:49 PM - StreetInsider
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
July 14, 2026 7:02 AM - Globe NewsWire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2026 7:30 AM - Globe NewsWire
Form 4 Kura Oncology, Inc. For: Jun 18 Filed by: Leoni Mollie
June 22, 2026 6:00 PM - SEC Filing
Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie
June 18, 2026 4:23 PM - SEC Filing
Kura Oncology (KURA) Reiterated at Market Outperform by Citizens After Data Presentation
June 15, 2026 5:13 AM - StreetInsider
Kura Oncology reports positive long-term cancer drug trial data
June 11, 2026 8:03 AM - StreetInsider
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
June 11, 2026 8:02 AM - Globe NewsWire
Full Article List
